+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Mirabegron Sustained-release Tablets Market - Global Forecast 2026-2032- Product Image
Mirabegron Sustained-release Tablets Market - Global Forecast 2026-2032- Product Image
Sale

Mirabegron Sustained-release Tablets Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6130302
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Mirabegron Sustained-release Tablets Market is projected to reach USD 3.21 Billion in 2026. It is expected to continue growing at a CAGR of 9.33%, reaching USD 5.48 Billion by 2032.

Mirabegron Sustained-Release Tablets: Executive Overview

Mirabegron sustained-release tablets are an oral pharmacological option for overactive bladder symptoms, including urgency, increased urinary frequency, and urge urinary incontinence. Their extended-release formulation is designed to support once-daily administration, while the product’s beta-3 adrenergic mechanism differentiates it from antimuscarinic therapies. Clinical use requires attention to indication, contraindications, blood-pressure considerations, drug interactions, renal and hepatic function, and local prescribing requirements.

Treatment Priorities Are Shifting Toward Tolerability and Persistence

The treatment landscape is increasingly shaped by the need to balance symptom control with tolerability, adherence, and patient-specific risk management. Mirabegron is relevant where anticholinergic burden, dry mouth, constipation, cognitive concerns, or inadequate persistence with antimuscarinic therapy influence treatment selection. Broader shifts include greater emphasis on shared decision-making, earlier identification of lower urinary tract symptoms, access to generic or lower-cost alternatives where available, and integration of behavioral measures with pharmacological treatment.

Artificial Intelligence Is Strengthening Evidence, Safety, and Care Pathways

Artificial intelligence can support this therapeutic area through structured analysis of electronic health records, identification of patients with persistent overactive bladder symptoms, and prediction of adherence or treatment discontinuation risks. Machine-learning tools may also assist pharmacovigilance by detecting potential safety signals across clinical and real-world data. However, responsible use requires validated datasets, transparent clinical reasoning, privacy safeguards, and clinician oversight; AI should complement, rather than replace, diagnosis and individualized prescribing.

Regional Insights: Access and Clinical Practice Vary Across Six Broad Markets

North America is characterized by established diagnostic pathways, insurance and formulary considerations, and attention to blood-pressure monitoring and treatment persistence. Latin America reflects varied reimbursement, regulatory, and specialist access conditions, making affordability and supply continuity important. Europe generally places strong emphasis on guideline alignment, health-technology assessment, and generic substitution, while the European Union combines common regulatory structures with national differences in reimbursement. The Middle East and Africa show substantial variation in specialist availability, procurement systems, and medicine access. Asia-Pacific spans highly developed markets and rapidly expanding healthcare systems, with differences in regulatory approval, local manufacturing, patient awareness, and urban-rural access.

Group Insights: Policy Blocs Shape Regulation, Procurement, and Access

ASEAN markets commonly require navigation of country-specific registration, reimbursement, and distribution systems despite regional cooperation. BRICS members represent diverse healthcare infrastructures, domestic pharmaceutical capabilities, and public procurement approaches, so access strategies need to be tailored rather than treated as uniform. The European Union benefits from coordinated regulatory principles but retains national pricing and reimbursement decisions. G7 markets generally emphasize robust evidence, pharmacovigilance, and structured reimbursement review. GCC countries often combine centralized or coordinated procurement with varied national regulatory processes. NATO membership is not a healthcare-market framework, but its members include diverse health systems where resilience of pharmaceutical supply chains and continuity of care remain relevant considerations.

Country Insights: Local Regulation and Reimbursement Remain Decisive

Australia’s access environment is influenced by national reimbursement assessment and primary-care prescribing. Brazil combines a large public health system with private-sector channels and state-level implementation differences. Canada’s provincial and territorial formularies materially affect coverage. China’s regulatory, procurement, and hospital-channel policies shape uptake, while India’s fragmented public and private delivery systems emphasize affordability and broad distribution. Japan has detailed regulatory and reimbursement processes, and South Korea combines national insurance administration with evidence-based coverage review. In Europe, France, Germany, Italy, Spain, and the United Kingdom differ in assessment, prescribing, and reimbursement pathways despite shared clinical standards. Mexico reflects mixed public-private access and varied institutional procurement. Russia presents distinct regulatory, procurement, and supply-chain conditions. In the United States, payer coverage, prior authorization, formulary placement, and clinician consideration of blood-pressure and interaction risks influence treatment access.

Action Priorities for Leaders: Build Evidence, Access, and Safety Around the Patient

Industry leaders should maintain clear, locally compliant evidence on efficacy, safety, dosing, interactions, and use in patients with renal or hepatic impairment. Patient-support initiatives should focus on correct administration, persistence, blood-pressure awareness, and prompt reporting of adverse effects without encouraging inappropriate self-medication. Commercial and access planning should distinguish public procurement, private insurance, specialist prescribing, and primary-care channels. Leaders should also strengthen pharmacovigilance, monitor regulatory changes, prepare reliable supply plans, and use real-world evidence responsibly to identify treatment gaps and improve shared decision-making.

Research Methodology: Evidence-Led Assessment of the Therapeutic Landscape

This executive summary uses the defined market scope of mirabegron sustained-release tablets and organizes findings across therapeutic practice, access conditions, technology, and geography. The assessment framework considers product characteristics, clinical guidance, regulatory expectations, reimbursement dynamics, safety monitoring, healthcare delivery, and patient adherence. Regional, group, and country observations are presented as qualitative comparisons based on recognized structural differences; no market estimates, shares, forecasts, or company-specific claims are included. Interpretation should be supplemented with current national labels, treatment guidelines, formulary decisions, and pharmacovigilance communications.

Conclusion: Responsible Positioning Depends on Patient Fit and Health-System Context

Mirabegron sustained-release tablets occupy a clinically relevant position in overactive bladder management, particularly when treatment tolerability, anticholinergic burden, adherence, and individualized risk assessment are central concerns. Their practical role varies by diagnosis, comorbidities, concomitant medicines, reimbursement, and local care pathways. Sustainable progress will depend on evidence-based prescribing, transparent safety communication, equitable access, dependable supply, and carefully governed use of digital and artificial-intelligence tools.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Mirabegron Sustained-release Tablets Market, by Dosage Strength
7.1. Introduction
7.2. 25 Mg
7.3. 50 Mg
8. Mirabegron Sustained-release Tablets Market, by Product Type
8.1. Introduction
8.2. Generic
8.3. Original
9. Mirabegron Sustained-release Tablets Market, by Indication
9.1. Introduction
9.2. Overactive Bladder
9.3. Urge Incontinence
10. Mirabegron Sustained-release Tablets Market, by Therapeutic Application
10.1. Introduction
10.2. Overactive Bladder (OAB)
10.2.1. Idiopathic Overactive Bladder
10.2.2. Neurogenic Overactive Bladder
10.2.3. Mixed Etiology Overactive Bladder
10.3. Neurogenic Detrusor Overactivity (NDO)
10.3.1. Spinal Cord Injury-related NDO
10.3.2. Multiple Sclerosis-related NDO
10.4. Urinary Incontinence
10.4.1. Urge Urinary Incontinence
10.4.2. Mixed Urinary Incontinence
11. Mirabegron Sustained-release Tablets Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Mirabegron Sustained-release Tablets Market, by End User
12.1. Introduction
12.2. Clinic
12.3. Home Care
12.4. Hospital
12.4.1. Private Hospital
12.4.2. Public Hospital
13. Mirabegron Sustained-release Tablets Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Mirabegron Sustained-release Tablets Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Mirabegron Sustained-release Tablets Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Alembic Pharmaceuticals Ltd.
17.2. Alkem Laboratories Ltd.
17.3. Amneal Pharmaceuticals LLC
17.4. Astellas Pharma Inc.
17.5. Cipla Limited
17.6. Dr. Reddy's Laboratories Ltd.
17.7. Intas Pharmaceuticals Ltd.
17.8. Ipca Laboratories Ltd.
17.9. Lupin Limited
17.10. MSN Laboratories
17.11. Sandoz International GmbH
17.12. Sun Pharmaceutical Industries Ltd.
17.13. Teva Pharmaceutical Industries Ltd.
17.14. Torrent Pharmaceuticals Ltd.
17.15. Viatris Inc.
17.16. Zydus Lifesciences
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Mirabegron Sustained-release Tablets Market, Years Considered for the Study
FIGURE 2. Global Mirabegron Sustained-release Tablets Market, Research Design
FIGURE 3. Global Mirabegron Sustained-release Tablets Market, Research Framework
FIGURE 4. Global Mirabegron Sustained-release Tablets Market, Data Triangulation
FIGURE 5. Global Mirabegron Sustained-release Tablets Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 7. Global Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Mirabegron Sustained-release Tablets Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 9. Global Mirabegron Sustained-release Tablets Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Mirabegron Sustained-release Tablets Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Mirabegron Sustained-release Tablets Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2025 vs 2032 (%)
FIGURE 13. Global Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Mirabegron Sustained-release Tablets Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Mirabegron Sustained-release Tablets Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Mirabegron Sustained-release Tablets Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Mirabegron Sustained-release Tablets Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Mirabegron Sustained-release Tablets Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Mirabegron Sustained-release Tablets Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Mirabegron Sustained-release Tablets Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Mirabegron Sustained-release Tablets Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Mirabegron Sustained-release Tablets Market Segmentation & Coverage
TABLE 2. Global Mirabegron Sustained-release Tablets Market Size, 2017-2032 (USD Million)
TABLE 3. Global Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 4. Global 25 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global 25 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global 25 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global 50 Mg Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global 50 Mg Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global 50 Mg Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 11. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Original Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Original Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Original Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 18. Global Overactive Bladder Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Overactive Bladder Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Overactive Bladder Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Urge Incontinence Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Urge Incontinence Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Urge Incontinence Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 25. Global Overactive Bladder (OAB) Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Overactive Bladder (OAB) Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Overactive Bladder (OAB) Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Idiopathic Overactive Bladder Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Idiopathic Overactive Bladder Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Idiopathic Overactive Bladder Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Neurogenic Overactive Bladder Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Neurogenic Overactive Bladder Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Neurogenic Overactive Bladder Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Mixed Etiology Overactive Bladder Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Mixed Etiology Overactive Bladder Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Mixed Etiology Overactive Bladder Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Neurogenic Detrusor Overactivity (NDO) Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Neurogenic Detrusor Overactivity (NDO) Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Neurogenic Detrusor Overactivity (NDO) Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Spinal Cord Injury-related NDO Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Spinal Cord Injury-related NDO Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Spinal Cord Injury-related NDO Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Multiple Sclerosis-related NDO Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Multiple Sclerosis-related NDO Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Multiple Sclerosis-related NDO Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Urinary Incontinence Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Urinary Incontinence Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Urinary Incontinence Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Urge Urinary Incontinence Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Urge Urinary Incontinence Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Urge Urinary Incontinence Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Mixed Urinary Incontinence Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Mixed Urinary Incontinence Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Mixed Urinary Incontinence Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 56. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Chain Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Chain Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Chain Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Independent Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Independent Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Independent Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 72. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Private Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Private Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Private Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Public Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Public Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Public Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Mirabegron Sustained-release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 100. North America Mirabegron Sustained-release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. North America Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 102. North America Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 103. North America Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 104. North America Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 105. North America Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 106. North America Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 107. North America Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 108. North America Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. North America Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 110. North America Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. North America Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 112. Latin America Mirabegron Sustained-release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Latin America Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 114. Latin America Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 115. Latin America Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 116. Latin America Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 117. Latin America Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 118. Latin America Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 119. Latin America Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 120. Latin America Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. Latin America Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 122. Latin America Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. Latin America Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 124. Europe Mirabegron Sustained-release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Europe Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 126. Europe Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. Europe Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. Europe Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 129. Europe Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 130. Europe Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 131. Europe Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 132. Europe Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 133. Europe Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 134. Europe Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. Europe Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 136. Middle East Mirabegron Sustained-release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Middle East Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 138. Middle East Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 139. Middle East Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 140. Middle East Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 141. Middle East Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 142. Middle East Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 143. Middle East Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 144. Middle East Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. Middle East Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 146. Middle East Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. Middle East Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 148. Africa Mirabegron Sustained-release Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. Africa Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 150. Africa Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 151. Africa Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 152. Africa Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 153. Africa Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 154. Africa Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 155. Africa Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 156. Africa Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. Africa Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 158. Africa Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. Africa Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 160. Global Mirabegron Sustained-release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. ASEAN Mirabegron Sustained-release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. ASEAN Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 163. ASEAN Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 164. ASEAN Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 165. ASEAN Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 166. ASEAN Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 167. ASEAN Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 168. ASEAN Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 169. ASEAN Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. ASEAN Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 171. ASEAN Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. ASEAN Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 173. GCC Mirabegron Sustained-release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 174. GCC Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 175. GCC Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 176. GCC Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. GCC Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 178. GCC Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 179. GCC Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 180. GCC Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 181. GCC Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. GCC Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 183. GCC Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. GCC Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 185. European Union Mirabegron Sustained-release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 186. European Union Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 187. European Union Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 188. European Union Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 189. European Union Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 190. European Union Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 191. European Union Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 192. European Union Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 193. European Union Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. European Union Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 195. European Union Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. European Union Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 197. BRICS Mirabegron Sustained-release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. BRICS Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 199. BRICS Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 200. BRICS Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. BRICS Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 202. BRICS Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 203. BRICS Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 204. BRICS Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 205. BRICS Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. BRICS Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 207. BRICS Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. BRICS Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 209. G7 Mirabegron Sustained-release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 210. G7 Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 211. G7 Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 212. G7 Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 213. G7 Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 214. G7 Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 215. G7 Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 216. G7 Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 217. G7 Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. G7 Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 219. G7 Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. G7 Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 221. NATO Mirabegron Sustained-release Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 222. NATO Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 223. NATO Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 224. NATO Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 225. NATO Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 226. NATO Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 227. NATO Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 228. NATO Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 229. NATO Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. NATO Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 231. NATO Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. NATO Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 233. Global Mirabegron Sustained-release Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 234. United States Mirabegron Sustained-release Tablets Market Size, 2017-2032 (USD Million)
TABLE 235. United States Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 236. United States Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 237. United States Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 238. United States Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 239. United States Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 240. United States Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 241. United States Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 242. United States Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. United States Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 244. United States Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. United States Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 246. Canada Mirabegron Sustained-release Tablets Market Size, 2017-2032 (USD Million)
TABLE 247. Canada Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 248. Canada Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 249. Canada Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. Canada Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 251. Canada Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 252. Canada Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 253. Canada Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 254. Canada Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. Canada Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 256. Canada Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Canada Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 258. Mexico Mirabegron Sustained-release Tablets Market Size, 2017-2032 (USD Million)
TABLE 259. Mexico Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 260. Mexico Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 261. Mexico Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 262. Mexico Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 263. Mexico Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 264. Mexico Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 265. Mexico Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 266. Mexico Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 267. Mexico Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 268. Mexico Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. Mexico Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 270. Brazil Mirabegron Sustained-release Tablets Market Size, 2017-2032 (USD Million)
TABLE 271. Brazil Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 272. Brazil Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 273. Brazil Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 274. Brazil Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 275. Brazil Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 276. Brazil Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 277. Brazil Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 278. Brazil Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 279. Brazil Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 280. Brazil Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. Brazil Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 282. United Kingdom Mirabegron Sustained-release Tablets Market Size, 2017-2032 (USD Million)
TABLE 283. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 284. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 285. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 286. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 287. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 288. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 289. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 290. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 291. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 292. United Kingdom Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 293. United Kingdom Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 294. Germany Mirabegron Sustained-release Tablets Market Size, 2017-2032 (USD Million)
TABLE 295. Germany Mirabegron Sustained-release Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 296. Germany Mirabegron Sustained-release Tablets Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 297. Germany Mirabegron Sustained-release Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 298. Germany Mirabegron Sustained-release Tablets Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 299. Germany Mirabegron Sustained-release Tablets Market Size, by Overactive Bladder (OAB), 2017-2032 (USD Million)
TABLE 300. Germany Mirabegron Sustained-release Tablets Market Size, by Neurogenic Detrusor Overactivity (NDO), 2017-2032 (USD Million)
TABLE 301. Germany Mirabegron Sustained-release Tablets Market Size, by Urinary Incontinence, 2017-2032 (USD Million)
TABLE 302. Germany Mirabegron Sustained-release Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 303. Germany Mirabegron Sustained-release Tablets Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 304. Germany Mirabegron Sustained-release Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 305. Germany Mirabegron Sustained-release Tablets Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 306. France Mirabegron Sustained-release Tablets Market Size, 2017-2032 (USD Million)
TABLE 307. France Mirabegron Sustained-rele

Companies Mentioned

  • Alembic Pharmaceuticals Ltd.
  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Intas Pharmaceuticals Ltd.
  • Ipca Laboratories Ltd.
  • Lupin Limited
  • MSN Laboratories
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Lifesciences

Related Topics

Related Reports

Mirabegron Drugs Market - Global Forecast 2026-2032 - Product Image

Mirabegron Drugs Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report - Product Image

Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Overactive Bladder Treatment Market - Global Forecast 2026-2032 - Product Image

Overactive Bladder Treatment Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Overactive Bladder Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Overactive Bladder Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 130 Pages
  • Global
From
Overactive Bladder Treatment Market Report 2026 - Product Image

Overactive Bladder Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.